Abstract:Molecular magnetic resonance imaging (MRI) of tumors improves the specificity of MRI by using targeted probes conjugated to contrast-generating metals. The limitation of this approach is in the identification of a target molecule present in sufficient concentration for visualization and the development of a labeling reagent that can penetrate tumor tissue with the fast kinetics required for use in a clinical setting. The receptor protein tyrosine phosphatase PTPµ is a transmembrane protein that is continuously proteolyzed in the tumor microenvironment to generate a high concentration of extracellular fragment that can be recognized by the SBK2 probe. We conjugated the SBK2 peptide to a gadolinium chelate [SBK2-Tris-(Gd-DOTA)3] to test whether the SBK2 probe could be developed as an MR molecular imaging probe. When intravenously injected into mice bearing flank tumors of human glioma cells, SBK2-Tris-(Gd-DOTA)3 labeled the tumors within 5 minutes with a high level of contrast for up to 2 hours post-injection. The contrast enhancement of SBK2-Tris-(Gd-DOTA)3 was significantly higher than that observed with a current MRI macrocyclic gadolinium chelate (Gadoteridol, ProHance) alone or a scrambled control. These results demonstrate that SBK2-Tris-(Gd-DOTA)3 labeling of the PTPµ extracellular fragment is a more specific MR molecular imaging probe than ProHance or a scrambled control. Consequently, the SBK2 probe may be more useful than the current gold standard reagent for MRI to identify tumors and to co-register tumor borders during surgical resection.

Salicylic Acid-Based Polymeric Contrast Agents for Molecular Magnetic Resonance Imaging of Prostate Cancer

Molecular Magnetic Resonance Imaging of Tumors with a PTPµ Targeted Contrast Agent.

A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen

Protein-Based Mri Contrast Agents for Molecular Imaging of Prostate Cancer

Acyl Hydrazides and Acyl Hydrazones As High-Performance Chemical Exchange Saturation Transfer MRI Contrast Agents.

In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles

Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.

Magnetic Resonance Imaging Contrast Agent: Crgd-Ferric Oxide Nanometer Particle and Its Role in the Diagnosis of Tumor

Gadolinium-based contrast agents for tumor targeting imaging

Multi-arm star-branched polymer as an efficient contrast agent for tumor-targeted magnetic resonance imaging

Salicylic Acid and Analogues As Diacest MRI Contrast Agents with Highly Shifted Exchangeable Proton Frequencies

Gadolinium(III)-based Polymeric Magnetic Resonance Imaging Agents for Tumor Imaging

Chemical Exchange Saturation Transfer (CEST) Agents: Quantum Chemistry and MRI

Repurposing Clinical Agents for Chemical Exchange Saturation Transfer Magnetic Resonance Imaging: Current Status and Future Perspectives

[Synthesis and Characterization of Biomacromolecular Conjugates for Magnetic Resonance Imaging].

Anthranilic Acid Analogs As Diamagnetic CEST MRI Contrast Agents That Feature an Intramolecular‐bond Shifted Hydrogen

A Ph-Responsive T1-T2 Dual-Modal MRI Contrast Agent for Cancer Imaging

Biocleavable Oligolysine-grafted Poly(disulfide amine)s as Magnetic Resonance Imaging Probes.

Protein MRI Contrast Agents as an Effective Approach for Precision Molecular Imaging

N-Aryl Amides As Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Contrast Agents.

Preparation of linear poly(glycerol) as a T1 contrast agent for tumor-targeted magnetic resonance imaging